Kasey Coyne
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1710379631
Payments from drug & device makers
Across 3 payments — averaging $104.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$153
- Amgen$145
- Amphastar Pharmaceuticals, Inc.$17
Across 6 payments — averaging $1829.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Recordati_rare_diseases_inc.$11K
What the payments were for
- Food & beverage$314100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 1 | $153 |
| Amgen | 1 | $145 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$314 in reported general payments places this provider in the 30th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $172,773 |
| ForteoTeriparatide | 22 | $88,356 |
| TrulicityDulaglutide | 54 | $71,321 |
| MounjaroTirzepatide | 42 | $56,940 |
| TymlosAbaloparatide | 21 | $55,393 |
| JanuviaSitagliptin Phosphate | 34 | $37,051 |
| JardianceEmpagliflozin | 21 | $25,237 |
| TradjentaLinagliptin | 12 | $15,312 |
| FarxigaDapagliflozin Propanediol | 16 | $13,885 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $10,894 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $9,986 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 47 | $8,580 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $8,457 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $6,821 |
| Novolog FlexpenInsulin Aspart | 18 | $4,678 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Chicago
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Wenyu HuangChicago$639K
- Silvana PannainChicago$575K
- Tamara VokesChicago$448K
- George BakrisChicago$429K
- William LoweChicago$372K
- Rajesh JainChicago$285K
- Louis PhilipsonChicago$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.